Skip to main content

Diabetes Drug Maker, Sues Over Compounded Versions of Mounjaro

Medically reviewed by Drugs.com.

By Cara Murez HealthDay Reporter

WEDNESDAY, Sept. 20, 2023 -- Another diabetes drug maker is taking legal action against businesses in several states, alleging that they’re “fraudulently claiming” that their compounded products are the same as its medication.

This time, it’s Eli Lilly suing certain medical spas, wellness centers and compounding pharmacies over its medication Mounjaro.

Mounjaro contains the active ingredient tirzepatide and is approved by the U.S. Food and Drug Administration to treat type 2 diabetes.

The lawsuits, filed Tuesday, are meant to stop the other companies from “the unlawful marketing and sale of non-FDA approved compounded products.”

“Lilly filed this lawsuit to protect patients,” the company said in a statement issued Tuesday. “Lilly cannot validate the safety or effectiveness of products claiming to contain tirzepatide that are not our own branded product.”

The company sells Mounjaro only in prefilled single-dose pens.

“These entities should be stopped from providing drug products in violation of consumer protection laws, particularly where they promise their patients that their drugs offer the same safety profile and clinical benefits as Mounjaro,” the statement added.

In June, Novo Nordisk sued businesses for making compounded versions of semaglutide, which is used in its type 2 diabetes drugs Ozempic and Rybelsus. The medication is also used to treat obesity under the brand name Wegovy.

In its cases, Novo Nordisk has asked the companies “to cease and desist from false advertising, trademark infringement and/or unlawful sales of non-FDA approved compounded products claiming to contain semaglutide.”

Eli Lilly said these compounded versions can cause “potentially serious health risks."

“Products claiming to contain tirzepatide that are made and/or distributed by compounding pharmacies or distributed by counterfeit sources have not been reviewed by the U.S. FDA or global regulatory agencies for safety, quality or efficacy," Eli Lilly said.

People have reported adverse events from compounded semaglutide, according to the FDA. The agency has said patients “should not use a compounded drug if an approved drug is available.”

However, Mounjaro has been on the agency's drug shortages list since last year, along with Ozempic and Wegovy.

“When a drug is in shortage, compounders may be able to prepare a compounded version of that drug if they meet certain requirements of the Federal Food, Drug, and Cosmetic (FD&C) Act,” the FDA said.

Sources

  • Eli Lilly & Co., news release, Sept. 19, 2023

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2023

Read this next

Mediterranean Diet Cuts Women's Risk of Early Death by 23%

FRIDAY, May 31, 2024 -- Experts have long extolled the benefits of the Mediterranean diet and a new study adds to that evidence, finding it cuts the odds for an early death in...

Ozempic Lowers Odds for Death, Illness in People With Kidney Disease and Type 2 Diabetes

FRIDAY, May 24, 2024 -- Ozempic provides a wide variety of health benefits for people with kidney disease and type 2 diabetes, a major clinical trial has found. The drug...

Costs, Side Effects Drive Folks to Quit New Weight-Loss Meds

THURSDAY, May 23, 2024 -- Three months after starting one of the new GLP-1 weight-loss drugs, more than a quarter of patients have already quit the medications, and by a year from...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.